pCODR gives initial positive recommendation for Ovarian Cancer Drug
pCODR recently announced their initial positive recommendation for Olaparib (Lynparza), a targeted therapy for ovarian cancer. As part of their recommendation, pCODR stated that "Reimbursement should be for olaparib monotherapy...
Read More